Clot Blog with Dr Sam Goldhaber

GARFIELD-AF: Room for Improvement in Both Men and Women Are women at risk for AF less likely to receive oral anticoagulation than men? Dr Goldhaber reviews data from a global registry.
Experts And Viewpoints, June 2015
London Bridge Is Falling Down Insights on bridging therapy when anticoagulation has to be interrupted, from the ORBIT-AF registry.
Experts And Viewpoints, June 2015
Dr Goldhaber Remembers Dr Michael J. Davidson Dr Goldhaber's poignant tribute to his colleague who was shot and killed at Brigham and Women's hospital.
Experts And Viewpoints, May 2015
Acute PE: Increased Role for Cardiologists Drs Goldhaber and Bilazarian discuss the cardiologist's increasing role in treating PE with the advent of NOACs.
Experts And Viewpoints, April 2015
GARFIELD-AF: Anticoagulation in the Real World Sam Goldhaber and John Camm discuss the international GARFIELD-AF registry, expected to bring a wealth of data about the use of anticoagulation in patients with atrial fibrillation.
Experts And Viewpoints, April 2015
RE-DUAL PCI: Testing Triple and Dual Therapy Regimens Dr Chris Cannon describes the RE-DUAL PCI trial, which will test triple vs dual therapy in patients with AF undergoing PCI.
Experts And Viewpoints, March 2015
Will INR Variability Replace Time in the Therapeutic Range? Dr Goldhaber looks at a new metric for assessing anticoagulation success.
Experts And Viewpoints, February 2015
Inflammation and Vascular Disease: Exciting Times Sam Goldhaber interviews Paul Ridker, who explains why the inflammatory hypothesis of vascular disease is alive and well despite the results of SOLID-TIMI 52.
Experts And Viewpoints, February 2015
NOAC Bleeding Lower In Meta-analysis Dr Goldhaber reviews a meta-analysis showing lower rates of bleeding for new oral anticoagulants vs warfarin.
Experts And Viewpoints, January 2015
Stroke Prevention in AF: Future Perspectives Samuel Goldhaber describes up-and-coming strategies for stroke prevention in patients with atrial fibrillation.
Experts And Viewpoints, January 2015
Warfarin Time in the Therapeutic Range: Room for Improvement Dr Samuel Goldhaber reviews a study of nationwide management of warfarin for stroke prevention in atrial fibrillation, showing poor real-world TTRs.
Experts And Viewpoints, December 2014
Warfarin in AF Patients on Dialysis: Worst of Both Worlds Samuel Goldhaber describes the shocking findings of a study of warfarin use for AF prevention in patients on hemodialysis.
Experts And Viewpoints, December 2014
The DAPT Trial: An Interview With Laura Mauri Samuel Goldhaber discusses the Duration of Dual Antiplatelet Therapy trial with lead investigator Laura Mauri.
Experts And Viewpoints, December 2014
Are Your Patients With AF Taking Their Anticoagulants? Samuel Goldhaber describes some sobering findings on anticoagulation adherence from a military healthcare database.
Experts And Viewpoints, November 2014
Thrombolysis for Pulmonary Embolism: A Meta-analysis Dr Samuel Goldhaber parses the good news and bad news from a meta-analysis of thrombolysis for PE.
Experts And Viewpoints, October 2014
Is Venous Thromboembolism a Chronic Condition? Dr Sam Goldhaber dispels the myth that venous thromboembolism is a one-time event treated with short-term management.
Experts And Viewpoints, October 2014
New and Improved: ESC Guidelines for Pulmonary Embolism Among Dr Goldhaber's highlights are better risk stratification and the inclusion of the novel oral anticoagulants.
Experts And Viewpoints, September 2014
PE Death in the Young and 'Healthy': What Are We Missing? Recent deaths in seemingly healthy young adults, including an American Idol finalist, prompts this blog from Dr. Goldhaber.
Experts And Viewpoints, August 2014
GARFIELD-AF Off and Running in the United States GARFIELD-AF coinvestigators Samuel Goldhaber and Gregory Piazza talk about US enrollment in this real-world registry of anticoagulation in atrial fibrillation.
Experts And Viewpoints, August 2014
AF Biomarkers, Genetics, and New ACC/AHA Guidelines Drs. Goldhaber and Ruff discuss current issues in AF management, including biomarkers, genotyping, and the new AF treatment guidelines.
Experts And Viewpoints, July 2014

« Previous

Clot Blog with Dr Sam Goldhaber

About

Membership

Apps

WebMD Network

Editions

Clot Blog with Dr Sam Goldhaber

Find Us On

About

Membership

Apps

WebMD Network

Editions